Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials.
Meticillin-resistant Staphylococcus aureus (MRSA) isolates from two worldwide ceftobiprole Phase 3 clinical trials for the treatment of complicated skin and skin-structure infections were characterised by clonality, staphylococcal cassette chromosome mec (SCCmec) type and the presence of Panton-Valentine leukocidin (PVL). PVL was predominantly found in US isolates (196/231 vs. 13/110 non-US isolates). SCCmec type IV was the most common (253/329) owing to the predominance of clone USA300 in isolates from the USA (197/226). In Europe, SCCmec type III was the most prevalent (30/74). Ceftobiprole minimum inhibitory concentrations (MICs) ranged from 0.25 microg/mL to 4 microg/mL, with MICs <or= 2 microg/mL for 99.7% of isolates, regardless of SCCmec or clone type.
Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJ 08869, USA. tdavies1@its.jnj.com
Todd A
TA
Davies
Wenchi
W
Shang
Karen M
KM
Amsler
Saralee
S
Bajaksouzian
Michael R
MR
Jacobs
Karen
K
Bush
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015373:Bacterial Typing Techniques / Q000379:methods; D002511:Cephalosporins / Q000627:therapeutic use*; D016000:Cluster Analysis; D016172:DNA Fingerprinting / Q000379:methods; D004269:DNA, Bacterial / Q000235:genetics; D005060:Europe; D005838:Genotype; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000145:classification* / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology*; D014481:United States
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004269:DNA, Bacterial; C443755:ceftobiprole